The concept of apolipoprotein-defined lipoprotein families and its clinical significance

被引：62
作者：
Petar Alaupovic
机构：
[1] Lipid and Lipoprotein Laboratory, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104
来源：
Current Atherosclerosis Reports | 2003年 / 5卷 / 6期
关键词：
Fenofibrate; Plasma Lipoprotein; Arterioscler Thromb Vasc Biol; Lipoprotein Particle; Lipoprotein Subclass;
D O I：
10.1007/s11883-003-0036-8
中图分类号：
学科分类号：
摘要：
Classification of plasma lipoproteins on the basis of apolipoprotein (apo) composition recognizes two lipoprotein (Lp) classes, one of which is characterized by apoA-I and the other by apoB as major protein constituents. The former lipoprotein class consists of three major subclasses referred to (according to their apolipoprotein constituents) as Lp-A-I, Lp-A-I:A-II, and Lp-A-II, and the latter one of five subclasses called Lp-B, Lp-B:E, Lp-B:C, Lp-B:C:E, and Lp-A-II:B:C:D:E. As polydisperse systems of particles, the apoA-I-containing lipoproteins overlap in high-density segments and apoB-containing lipoproteins in low-density segments of the density gradient. Each subclass is characterized by a specific chemical composition and metabolic property. Normolipidemia and dyslipoproteinemias are characterized by quantitative rather than qualitative differences in the levels of apoA- and apoB-containing subclasses. Furthermore, apoA-containing subclasses seem to differ with respect to their relative antiatherogenic capacities, and apoB-containing subclasses regarding their relative atherogenic potentials. Whereas Lp-A-I may have a greater antiatherogenic capacity than other apoA-containing subclasses, the cholesterol-enriched Lp-B:C appears to be the most atherogenic subclass among apoB-containing lipoprotein families. The use of pharmacologic and/or dietary interventions to treat dyslipoproteinemias has already shown that these therapeutic modalities may affect selectively individual apolipoprotein-defined lipoproteins, and thus allow the selection of individualized treatments targeted at decreasing harmful and/or increasing beneficial lipoprotein subclasses. Copyright © 2003 by Current Science Inc.
引用
收藏
页码：459 / 467
页数：8
相关论文
共 75 条
  • [1] Gofman J.W., De Lalla O., Glazier F., Et al., The serum lipoprotein transport system in health, metabolic disorders, atherosclerosis, and coronary heart disease, Plasma, 2, pp. 413-484, (1954)
  • [2] Jones H.B., Golman J.W., Lindgren F.T., Et al., Lipoproteins in atherosclerosis, Am. J. Med., 11, pp. 358-380, (1951)
  • [3] Nichols A.V., Human serum lipoproteins and their interrelationships, Adv. Biol. Med. Phys., 11, pp. 109-158, (1967)
  • [4] Fredrickson D.S., Levy R.I., Lees R.S., Fat transport in lipoproteins: An integrated approach to mechanism and disorders, N. Engl. J. Med., 276, pp. 32-281, (1967)
  • [5] Ewing A.M., Freeman N.K., Lindgren F.T., The analysis of human serum lipoprotein distributions, Adv. Lipid Res., 3, pp. 25-61, (1965)
  • [6] Nestel P., Billington T., Tada N., Et al., Heterogeneity of very-low-density lipoprotein metabolism in hyperlipidemic subjects, Metabolism, 32, pp. 810-817, (1983)
  • [7] Nestel P., High-density lipoprotein turnover, Am. Heart J., 113, pp. 518-521, (1987)
  • [8] Packard C.J., Shepherd J., Lipoprotein heterogeneity and apolipoprotein B metabolism, Arterioscler. Thromb. Vasc. Biol., 17, pp. 3542-3556, (1997)
  • [9] Alaupovic P., Conceptual development of the classification systems of plasma lipoproteins, Protides. Biol. Fluids Proc. Colloq., 19, pp. 9-19, (1972)
  • [10] Osborne Jr. J.C., Brewer Jr. H.B., The plasma lipoproteins, Adv. Protein. Chem., 31, pp. 253-337, (1977)
12345678